1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

Cymbalta (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • April 2014
  • 69 pages
  • GlobalData
Report ID: 2127343

Summary

Table of Contents

Cymbalta (Neuropathic Pain) - Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Cymbalta (duloxetine) is an SNRI that was developed by Eli Lilly and was initially approved in the US in August 2004 for the treatment of major depressive disorder (MDD). The drug was later approved for PDN in September 2004. Since then, Eli Lilly has accrued multiple indications for Cymbalta, such as GAD, fibromyalgia, and most recently, for the treatment of chronic musculoskeletal pain, including chronic osteoarthritis pain and chronic low back pain.

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cymbalta including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cymbalta for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cymbalta performance
- Obtain sales forecast for Cymbalta from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Spinal Cord Stimulators - Medical Devices Pipeline Assessment, 2017

  • $ 2500
  • Industry report
  • July 2017
  • by GlobalData

Spinal Cord Stimulators - Medical Devices Pipeline Assessment, 2017 Summary GlobalData’s Medical Devices sector report, “Spinal Cord Stimulators - Medical Devices Pipeline Assessment, 2017" provides ...

Diabetic Neuropathy Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • July 2017
  • by GlobalData

Diabetic Neuropathy Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Diabetic Neuropathy Global Clinical Trials Review, H2, 2017" provides an overview of Diabetic ...

Diabetic Peripheral Neuropathy Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • July 2017
  • by GlobalData

Diabetic Peripheral Neuropathy Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Diabetic Peripheral Neuropathy Global Clinical Trials Review, H2, 2017" provides ...


Download Unlimited Documents from Trusted Public Sources

Anxiety Disorder and Mental Health Statistics in the US

  • September 2017
    37 pages
  • Anxiety Disorde...  

    Mental Health  

    Addictions  

  • United States  

View report >

Digestive System Disorder Statistics in Iran

  • September 2017
    184 pages
  • Digestive Syste...  

    Mortality  

    Hospital  

  • Iran  

View report >

Global Mental Health Statistics

  • September 2017
    35 pages
  • Neurological Di...  

    Mental Health  

    Dementia  

  • World  

View report >

Related Market Segments :

Chronic Pain
Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.